Open Label Extension for GLYX13-C-202, NCT01684163
Public ClinicalTrials.gov record NCT02192099. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2, Open Label Extension for Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder Previously Treated With GLYX-13 (Extension of GLYX13-C-202, NCT01684163)
Study identification
- NCT ID
- NCT02192099
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Naurex, Inc, an affiliate of Allergan plc
- Industry
- Enrollment
- 61 participants
Conditions and interventions
Conditions
Interventions
- Rapastinel (225 mg/450 mg IV administration) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 7, 2014
- Primary completion
- Nov 7, 2018
- Completion
- Nov 7, 2018
- Last update posted
- Nov 26, 2019
2014 – 2018
United States locations
- U.S. sites
- 10
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Office of Psychiatric Research | Birmingham | Alabama | 35294 | — |
| Artemis Institute for Clinical Research | San Diego | California | 92103 | — |
| Chicago Research Center | Chicago | Illinois | 60634 | — |
| University of Kansas School of Medicine Clinical Trial Unit | Wichita | Kansas | 67214 | — |
| PharmaSite Research, Inc. | Baltimore | Maryland | 21208 | — |
| Boston Clinical Trials Inc. | Roslindale | Massachusetts | 02131 | — |
| Woodlands Professional Princeton Medical Institute Building | Princeton | New Jersey | 08540 | — |
| Finger Lake Clinical Research | Rochester | New York | 14618 | — |
| Lindner Center of HOPE | Mason | Ohio | 45040 | — |
| PRA Health Sciences Phase 2/3 Outpatient & CNS Clinic | Salt Lake City | Utah | 84107 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02192099, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 26, 2019 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02192099 live on ClinicalTrials.gov.